Clinical Trial Update: A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) [Phase 2, Phase 3]

View source ↗

Summary

Phase II/Phase III clinical trial evaluating intravenous melphalan with autologous whole blood stem cell transplantation in castration-resistant prostate cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Melphalan (Melphalan)

Snippet

Sponsor: Barts & The London NHS Trust | Conditions: Castrate Resistant Prostate Cancer | Phase 2, Phase 3 | Status: TERMINATED